Which has higher earnings & valuation, EOLS or VCEL?

Vericel has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evolus $297.18M 1.48 -$51.64M -$0.67 N/A Vericel $292.09M 6.25 $16.52M $0.42 85.17

Is EOLS or VCEL more profitable?

Vericel has a net margin of 7.35% compared to Evolus' net margin of -14.39%. Vericel's return on equity of 6.41% beat Evolus' return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Vericel 7.35% 6.41% 4.61%

Does the media refer more to EOLS or VCEL?

In the previous week, Vericel had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Vericel and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Vericel's score of 0.00 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vericel 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PVLA or EOLS?

In the previous week, Palvella Therapeutics had 5 more articles in the media than Evolus. MarketBeat recorded 6 mentions for Palvella Therapeutics and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Palvella Therapeutics' score of 0.53 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Palvella Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TSHA or EOLS?

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Taysha Gene Therapies' score of 0.33 indicating that Evolus is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, EOLS or ATAI?

Evolus has higher revenue and earnings than Atai Beckley. Evolus is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Evolus $297.18M 1.48 -$51.64M -$0.67 N/A Atai Beckley $3.49M 402.15 -$660.05M -$2.23 N/A

Is EOLS or ATAI more profitable?

Evolus has a net margin of -14.39% compared to Atai Beckley's net margin of -19,019.44%. Evolus' return on equity of 0.00% beat Atai Beckley's return on equity. Company Net Margins Return on Equity Return on Assets Evolus -14.39% N/A -19.03% Atai Beckley -19,019.44% -89.79% -63.58%

Does the media favor EOLS or ATAI?

In the previous week, Atai Beckley had 7 more articles in the media than Evolus. MarketBeat recorded 8 mentions for Atai Beckley and 1 mentions for Evolus. Atai Beckley's average media sentiment score of 1.04 beat Evolus' score of 0.91 indicating that Atai Beckley is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Atai Beckley 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor EOLS or GLUE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Monte Rosa Therapeutics' score of 0.00 indicating that Evolus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evolus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Evolus (EOLS) Competitors

$6.68 +0.01 (+0.15%)

Closing price 06/8/2026 04:00 PM Eastern

Extended Trading

$6.68 0.00 (0.00%)

As of 07:43 AM Eastern

Compare

EOLS vs. VCEL, PVLA, TSHA, ATAI, and GLUE

Should you buy Evolus stock or one of its competitors? MarketBeat compares Evolus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Evolus include Vericel (VCEL), Palvella Therapeutics (PVLA), Taysha Gene Therapies (TSHA), Atai Beckley (ATAI), and Monte Rosa Therapeutics (GLUE). These companies are all part of the "pharmaceutical products" industry.

How does Evolus compare to Vericel?

Evolus (NASDAQ:EOLS) and Vericel (NASDAQ:VCEL) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

Evolus presently has a consensus price target of $16.00, suggesting a potential upside of 139.52%. Vericel has a consensus price target of $55.40, suggesting a potential upside of 54.88%. Given Evolus' higher probable upside, research analysts clearly believe Evolus is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Vericel	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Evolus has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, Vericel has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Vericel has a net margin of 7.35% compared to Evolus' net margin of -14.39%. Vericel's return on equity of 6.41% beat Evolus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Vericel	7.35%	6.41%	4.61%

Vericel has lower revenue, but higher earnings than Evolus. Evolus is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.48	-$51.64M	-$0.67	N/A
Vericel	$292.09M	6.25	$16.52M	$0.42	85.17

90.7% of Evolus shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 7.6% of Vericel shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Vericel had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Vericel and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Vericel's score of 0.00 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vericel	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vericel beats Evolus on 10 of the 15 factors compared between the two stocks.

How does Evolus compare to Palvella Therapeutics?

Palvella Therapeutics (NASDAQ:PVLA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Palvella Therapeutics presently has a consensus target price of $199.53, indicating a potential upside of 89.58%. Evolus has a consensus target price of $16.00, indicating a potential upside of 139.52%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.94
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Palvella Therapeutics had 5 more articles in the media than Evolus. MarketBeat recorded 6 mentions for Palvella Therapeutics and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Palvella Therapeutics' score of 0.53 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Palvella Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

40.1% of Palvella Therapeutics shares are held by institutional investors. Comparatively, 90.7% of Evolus shares are held by institutional investors. 20.5% of Palvella Therapeutics shares are held by company insiders. Comparatively, 5.0% of Evolus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Palvella Therapeutics has higher earnings, but lower revenue than Evolus. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Palvella Therapeutics	N/A	N/A	-$41.72M	-$4.17	N/A
Evolus	$297.18M	1.48	-$51.64M	-$0.67	N/A

Palvella Therapeutics has a beta of -0.15, meaning that its stock price is 115% less volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Palvella Therapeutics has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Palvella Therapeutics	N/A	-56.87%	-42.50%
Evolus	-14.39%	N/A	-19.03%

Summary

Evolus beats Palvella Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Evolus compare to Taysha Gene Therapies?

Taysha Gene Therapies (NASDAQ:TSHA) and Evolus (NASDAQ:EOLS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, profitability, valuation, earnings, institutional ownership and risk.

Taysha Gene Therapies has a net margin of 0.00% compared to Evolus' net margin of -14.39%. Evolus' return on equity of 0.00% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Evolus	-14.39%	N/A	-19.03%

Evolus has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$9.77M	159.71	-$109M	-$0.38	N/A
Evolus	$297.18M	1.48	-$51.64M	-$0.67	N/A

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 90.7% of Evolus shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 5.0% of Evolus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Taysha Gene Therapies currently has a consensus price target of $11.64, suggesting a potential upside of 114.30%. Evolus has a consensus price target of $16.00, suggesting a potential upside of 139.52%. Given Evolus' higher probable upside, analysts clearly believe Evolus is more favorable than Taysha Gene Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Taysha Gene Therapies had 4 more articles in the media than Evolus. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Taysha Gene Therapies' score of 0.33 indicating that Evolus is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market.

Summary

Evolus beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does Evolus compare to Atai Beckley?

Evolus (NASDAQ:EOLS) and Atai Beckley (NASDAQ:ATAI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Evolus has a net margin of -14.39% compared to Atai Beckley's net margin of -19,019.44%. Evolus' return on equity of 0.00% beat Atai Beckley's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Atai Beckley	-19,019.44%	-89.79%	-63.58%

Evolus has higher revenue and earnings than Atai Beckley. Evolus is trading at a lower price-to-earnings ratio than Atai Beckley, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.48	-$51.64M	-$0.67	N/A
Atai Beckley	$3.49M	402.15	-$660.05M	-$2.23	N/A

In the previous week, Atai Beckley had 7 more articles in the media than Evolus. MarketBeat recorded 8 mentions for Atai Beckley and 1 mentions for Evolus. Atai Beckley's average media sentiment score of 1.04 beat Evolus' score of 0.91 indicating that Atai Beckley is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Atai Beckley	6 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Evolus has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, Atai Beckley has a beta of 1.6, suggesting that its share price is 60% more volatile than the broader market.

90.7% of Evolus shares are held by institutional investors. Comparatively, 28.4% of Atai Beckley shares are held by institutional investors. 5.0% of Evolus shares are held by company insiders. Comparatively, 26.8% of Atai Beckley shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Evolus currently has a consensus target price of $16.00, suggesting a potential upside of 139.52%. Atai Beckley has a consensus target price of $16.00, suggesting a potential upside of 319.95%. Given Atai Beckley's stronger consensus rating and higher probable upside, analysts plainly believe Atai Beckley is more favorable than Evolus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Atai Beckley	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Atai Beckley beats Evolus on 10 of the 17 factors compared between the two stocks.

How does Evolus compare to Monte Rosa Therapeutics?

Evolus (NASDAQ:EOLS) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.

Evolus has a beta of 1.34, meaning that its stock price is 34% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the broader market.

Monte Rosa Therapeutics has lower revenue, but higher earnings than Evolus. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Evolus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evolus	$297.18M	1.48	-$51.64M	-$0.67	N/A
Monte Rosa Therapeutics	$42.95M	33.44	-$38.63M	-$1.48	N/A

90.7% of Evolus shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 5.0% of Evolus shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Evolus. MarketBeat recorded 2 mentions for Monte Rosa Therapeutics and 1 mentions for Evolus. Evolus' average media sentiment score of 0.91 beat Monte Rosa Therapeutics' score of 0.00 indicating that Evolus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Evolus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Evolus currently has a consensus target price of $16.00, indicating a potential upside of 139.52%. Monte Rosa Therapeutics has a consensus target price of $32.50, indicating a potential upside of 91.18%. Given Evolus' higher possible upside, analysts clearly believe Evolus is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evolus	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Evolus has a net margin of -14.39% compared to Monte Rosa Therapeutics' net margin of -302.69%. Evolus' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Evolus	-14.39%	N/A	-19.03%
Monte Rosa Therapeutics	-302.69%	-40.99%	-25.94%

Summary

Evolus beats Monte Rosa Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Evolus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EOLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EOLS vs. The Competition

Export

Metric	Evolus	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$439.25M	$8.40B	$6.48B	$11.99B
Dividend Yield	N/A	2.52%	2.67%	5.58%
P/E Ratio	-9.97	16.16	23.67	23.74
Price / Sales	1.48	7.06	527.02	119.88
Price / Cash	N/A	17.45	26.99	37.25
Price / Book	-18.56	3.55	10.44	6.78
Net Income	-$51.64M	$225.32M	$3.57B	$337.51M
7 Day Performance	8.27%	0.58%	0.26%	-2.34%
1 Month Performance	5.03%	2.21%	3.24%	1.88%
1 Year Performance	-30.78%	-3.45%	22.22%	25.55%

Evolus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EOLS Evolus	3.074 of 5 stars	$6.68 +0.1%	$16.00 +139.5%	-33.5%	$439.25M	$297.18M	N/A	170
VCEL Vericel	2.4688 of 5 stars	$32.82 -1.5%	$55.40 +68.8%	-17.4%	$1.70B	$276.26M	78.14	300	Analyst Upgrade
PVLA Palvella Therapeutics	2.959 of 5 stars	$112.59 -5.0%	$199.53 +77.2%	+314.4%	$1.70B	$42.81M	N/A	N/A
TSHA Taysha Gene Therapies	3.5605 of 5 stars	$5.97 +1.7%	$11.64 +94.9%	+91.2%	$1.69B	$9.77M	N/A	180
ATAI Atai Beckley	3.5959 of 5 stars	$4.82 +6.4%	$16.00 +232.0%	+58.1%	$1.67B	$4.09M	N/A	80	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EOLS) was last updated on 6/9/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Evolus (EOLS) Competitors

EOLS vs. VCEL, PVLA, TSHA, ATAI, and GLUE

How does Evolus compare to Vericel?

Summary

How does Evolus compare to Palvella Therapeutics?

Summary

How does Evolus compare to Taysha Gene Therapies?

Summary

How does Evolus compare to Atai Beckley?

Summary

How does Evolus compare to Monte Rosa Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Evolus (EOLS) Competitors

EOLS vs. VCEL, PVLA, TSHA, ATAI, and GLUE

How does Evolus compare to Vericel?

Do analysts prefer EOLS or VCEL?

Which has more volatility and risk, EOLS or VCEL?

Is EOLS or VCEL more profitable?

Which has higher earnings & valuation, EOLS or VCEL?

Do institutionals and insiders have more ownership in EOLS or VCEL?

Does the media refer more to EOLS or VCEL?

Summary

How does Evolus compare to Palvella Therapeutics?

Do analysts recommend PVLA or EOLS?

Does the media favor PVLA or EOLS?

Do insiders & institutionals believe in PVLA or EOLS?

Which has higher valuation and earnings, PVLA or EOLS?

Which has more risk & volatility, PVLA or EOLS?

Is PVLA or EOLS more profitable?

Summary

How does Evolus compare to Taysha Gene Therapies?

Is TSHA or EOLS more profitable?

Which has higher valuation & earnings, TSHA or EOLS?

Do insiders and institutionals hold more shares of TSHA or EOLS?

Do analysts prefer TSHA or EOLS?

Does the media favor TSHA or EOLS?

Which has more volatility & risk, TSHA or EOLS?

Summary

How does Evolus compare to Atai Beckley?

Is EOLS or ATAI more profitable?

Which has better earnings and valuation, EOLS or ATAI?

Does the media favor EOLS or ATAI?

Which has more volatility and risk, EOLS or ATAI?

Do insiders & institutionals hold more shares of EOLS or ATAI?

Do analysts prefer EOLS or ATAI?

Summary

How does Evolus compare to Monte Rosa Therapeutics?

Which has more volatility & risk, EOLS or GLUE?

Which has stronger valuation & earnings, EOLS or GLUE?

Do insiders & institutionals believe in EOLS or GLUE?

Does the media favor EOLS or GLUE?

Do analysts recommend EOLS or GLUE?

Is EOLS or GLUE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EOLS vs. The Competition

Evolus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools